First-Ever Personalized CRISPR Therapy Successfully Treats Baby with Ultra-Rare Metabolic Disorder

A baby born with a life-threatening ultra-rare metabolic disorder has become the first patient worldwide to receive a personalized CRISPR gene therapy designed specifically for his unique genetic mutation. The landmark treatment, developed by researchers at Children's Hospital of Philadelphia (CHOP) and Penn Medicine, represents a paradigm shift toward truly individualized medicine for rare genetic diseases.

Baby KJ was diagnosed with severe carbamoyl phosphate synthetase 1 (CPS1 (search)Search target) deficiency within days of birth following metabolic crises. This urea-cycle disorder prevents the liver from converting ammonia into urea for safe excretion, causing toxic ammonia buildup that often leads to irreversible brain damage or death. About 50% of infants with the most severe neonatal-onset form die early in life, while survivors typically face profound neurological impairment.

Rapid Development of Bespoke Therapy

Remarkably, within just six months of KJ's diagnosis, the research team designed, tested, manufactured, and gained regulatory clearance for a CRISPR base-editing therapy specific to his mutation. The therapeutic payload was packaged into lipid nanoparticles to facilitate delivery to the liver.

"Years and years of progress in gene editing and collaboration between researchers and clinicians made this moment possible, and while KJ is just one patient, we hope he is the first of many to benefit from a methodology that can be scaled to fit an individual patient's needs," said Rebecca Ahrens-Nicklas, director of the Gene Therapy for Inherited Metabolic Disorders Frontier Program at CHOP and assistant professor of pediatrics in the Perelman School of Medicine.

KJ received his first infusion on February 25, 2025, when he was around seven months old, followed by additional doses in March and April.

Promising Clinical Outcomes

According to clinical reports, KJ tolerated all doses without serious adverse events. In the seven weeks following the initial infusion, he was able to tolerate increased dietary protein and had his nitrogen-scavenger medication dose halved. These metabolic improvements persisted even during viral illnesses, episodes that previously might have triggered dangerous ammonia spikes.

By mid-2025, KJ had been discharged from hospital and was "thriving," according to his care team. Parents and clinicians described him meeting developmental milestones previously thought unlikely in such severe cases.

"We've been in the thick of this since KJ was born, and our whole world's been revolving around this little guy and his stay in the hospital," his father, Kyle Muldoon, said. "We're so excited to be able to finally be together at home so that KJ can be with his siblings, and we can finally take a deep breath."

Transforming Rare Disease Treatment

Until now, gene therapies typically targeted conditions shared by many patients, enabling economies of scale. However, most genetic disorders are rare or ultra-rare, often involving unique "private" mutations. KJ's case demonstrates that with modern base-editing technology, lipid-nanoparticle delivery, and rapid development, truly personalized, single-patient therapies are feasible.

Co-corresponding author Kiran Musunuru, the Barry J. Gertz Professor for Translational Research in Penn's Perelman School of Medicine, emphasized the broader implications: "We want each and every patient to have the potential to experience the same results we saw in this first patient, and we hope that other academic investigators will replicate this method for many rare diseases and give many patients a fair shot at living a healthy life."

The collaborative effort between Drs. Ahrens-Nicklas and Musunuru began in 2023, building upon years of research into rare metabolic disorders and genome editing feasibility. Both are members of the NIH-funded Somatic Cell Genome Editing Consortium.

Addressing Critical Unmet Need

Typically, patients with CPS1 (search)Search target deficiency are treated with liver transplantation, the only curative option available. However, patients must be medically stable and old enough to handle such a major procedure. During the waiting period, episodes of increased ammonia can cause ongoing neurologic damage or prove fatal.

"We thought it was our responsibility to help our child, so when the doctors came to us with their idea, we put our trust in them in the hopes that it could help not just KJ but other families in our position," said his mother, Nicole Muldoon.

Future Implications and Challenges

While results are encouraging, experts emphasize that long-term follow-up remains essential to monitor for durability of gene correction, safety, and neurodevelopmental outcomes. The ethical, regulatory and manufacturing challenges of scaling personalized therapies remain substantial.

Nevertheless, researchers involved in the case describe this treatment as a "blueprint" for similar bespoke therapies that could be tailored rapidly for other rare metabolic or genetic diseases. The case signals a paradigm shift from "one-size-fits-many" to "one-size-fits-one" medicine.

"The promise of gene therapy that we've heard about for decades is coming to fruition, and it's going to utterly transform the way we approach medicine," Dr. Musunuru said.

The study was published in the New England Journal of Medicine and presented at the American Society of Gene & Cell Therapy Annual Meeting in New Orleans, supported by grants from the National Institutes of Health Somatic Cell Genome Editing Program and additional NIH funding.